FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality

The Food and Drug Administration is asking one of its panels of outside experts to help it make a decision about GlaxoSmithKline's (NYSE:GSK) request to add data to the label of Trelegy Ellipta, its chronic obstructive pulmonary disease (COPD) drug. The pulmonary-allergy drugs advisory committee will meet on April 21 to discuss whether the claim that Trelegy Ellipta reduces mortality should be added to the drug's label. That would allow the company to use the information in its marketing materials.